Entering text into the input field will update the search result below

The blind squirrel found an acorn in ZymoGentics -- ZGEN

Sep. 08, 2010 10:21 AM ETZGEN-OLD, BMY
Jim Van Meerten profile picture
Jim Van Meerten's Blog
66.05K Followers
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

One of the advantages of buying stocks that are beginning to hit new highs and show upward price movements is that you will find that a good number of your positions are merger and acquisition targets. Prices do move up just before the acquisition news is released.

Last Friday we bought ZymoGentics (ZGEN) in the Barchart Van Meerten Speculative portfolio for an average cost of 5.48 a share and on Tuesday after the markets closed

Bristol-Myers (BYM) made a 9.75 bid for the stock. This morning we closed out our position at an average price of 9.71 for a profit of 77% during our 2 trading day holding period,

Some of you are probably wondering why I don't stick it out to see if a higher bid comes in but I find that a bird in the hand is worth two in the bush. I'll take my profits and reinvest into a new stock.

Jim Van Meerten is an investor who writes on investing here and on Barchart Portfolio Blogs. Please leave a comment below or email JimVanMeerten@gmail.com.



Disclosure: No position at the time of publication

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You